Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone

Leuk Res. 2010 Nov;34(11):1453-8. doi: 10.1016/j.leukres.2010.01.011. Epub 2010 Jan 31.

Abstract

The role of TNF-α promoter polymorphisms in the development of multiple myeloma (MM) were tested in 210 patients and 218 healthy individuals and their impact on the clinical outcome were evaluated in 98 patients treated with thalidomide and dexamethasone (Thal+Dex) regimen. MM patients carrying the GA genotype (P=0.01) or GA+AA genotypes (P=0.02) at the TNF-α -308 polymorphism were associated with a reduced risk for MM. The TNF-α -238 GA+AA genotypes were associated with a significant enhancement in the progression-free survival (PFS) (P=0.009) and a better overall survival (OS) (P=0.088).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Case-Control Studies
  • Dexamethasone / administration & dosage
  • Disease-Free Survival
  • Female
  • Genetic Predisposition to Disease / genetics
  • Genotype
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma / diagnosis
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / genetics*
  • Multiple Myeloma / mortality
  • Polymorphism, Genetic*
  • Promoter Regions, Genetic*
  • Survival Rate
  • Thalidomide / administration & dosage
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / genetics*

Substances

  • Tumor Necrosis Factor-alpha
  • Thalidomide
  • Dexamethasone